Pure Global AI
NCT05692050No longer available

Expanded Access to Epcoritamab

AbbVieClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Lymphoma
Drug/Device/Intervention
Epcoritamab
Study type
Expanded access
Intervention type
drug
Sponsor & location
Primary sponsor
AbbVie
Timeline & enrollment
Phase
N/A
Start date
N/A
End date
N/A
Summary

This is an expanded access program (EAP) for eligible participants. This program is designed
 to provide access to epcoritamab prior to approval by the local regulatory agency.
 Availability will depend on territory eligibility. A medical doctor must decide whether the
 potential benefit outweighs the risk of receiving an investigational therapy based on the
 individual patient's medical history and program eligibility criteria.

ICD-10 classifications
Hodgkin lymphomaFollicular lymphomaNon-Hodgkin lymphoma, unspecifiedFollicular lymphoma, unspecifiedHodgkin lymphoma, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05692050
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05692050 through Pure Global AI's free database. This phase not specified trial is sponsored by AbbVie and is currently No longer available. The study focuses on Lymphoma.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.